BONESUPPORT reported Q4 FY2025 net sales of SEK 312.5 million, up 21.6%, with gross margin of 92.5%. Operating result was SEK 81.8 million and adjusted operating result was SEK 81.3 million, while net income for the period was SEK 44.1 million. Earnings per share were SEK 0.67 before dilution and SEK 0.66 after dilution. Operating cash flow was SEK 53.8 million and cash at period-end was SEK 378.0 million, with net cash of SEK 366.3 million. For FY2025, net sales were SEK 1.2 billion, up 30.7%, with gross margin of 92.6%. Operating result was SEK 231.7 million and adjusted operating result was SEK 262.0 million; net income was SEK 142.2 million, with EPS of SEK 2.16 before dilution and SEK 2.13 after dilution. Operating cash flow was SEK 221.3 million. In the US segment, Q4 sales were SEK 258.8 million, up 24.0%, driven by CERAMENT G sales of SEK 206.9 million. EUROW Q4 sales were SEK 53.8 million, up 13.0%, with antibiotic-eluting products accounting for 91% of segment sales. The company said its FDA application for CERAMENT V in bone infection was moved from a 510(k) to a De Novo process in December, and reiterated guidance for 2026 sales growth exceeding 35% at constant exchange rates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bonesupport Holding AB published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.